ANDRAS HECZEY to Mice
This is a "connection" page, showing publications ANDRAS HECZEY has written about Mice.
Connection Strength
0.244
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.
Score: 0.052
-
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol Res. 2020 03; 8(3):309-320.
Score: 0.041
-
Alliance of the Titans: An Effective Combination of a TKI with CAR T Cells. Mol Ther. 2019 08 07; 27(8):1348-1349.
Score: 0.040
-
Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Hum Gene Ther. 2017 05; 28(5):437-448.
Score: 0.032
-
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014 Oct 30; 124(18):2824-33.
Score: 0.028
-
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 Apr; 80(4):610-621.
Score: 0.014
-
Targeting Lin28 axis enhances glypican-3-CAR T?cell efficacy against hepatic tumor initiating cell population. Mol Ther. 2023 03 01; 31(3):715-728.
Score: 0.013
-
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.
Score: 0.010
-
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016 06 01; 126(6):2341-55.
Score: 0.008
-
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012 Jun; 122(6):2221-33.
Score: 0.006